Maridebart cafraglutide

Fat LossInvestigational GIP antagonist / GLP-1 agonist antibody-peptideEmerging

Also known as: MariTide, AMG 133

Maridebart cafraglutide (also called MariTide or AMG 133) is an investigational GIP antagonist in the GLP-1 Agonist class. Maridebart cafraglutide is an antibody-peptide conjugate with an unusual design: it antagonises the GIP receptor while activating the GLP-1 receptor. A monoclonal antibody against GIPR is conjugated to GLP-1 analog peptides, so one molecule blocks one incretin receptor and stimulates the other.

Calculate Dose

For research use only.

Key Facts

CAS
2760218-55-9
Molecular Weight (MW)
≈145–154 kDa (conjugate; assay-dependent)
Half-life
Long (monthly or less frequent dosing in trials)
FDA status
Investigational New Drug (IND)
Evidence level
Clinical Trial Evidence
Human dose established
Yes
Administration Route
Subcutaneous
Frequency
Every 4 weeks or every 8 weeks
Last updated
Nov 7, 2026
Reviewed
Nov 7, 2026
Targets
GIP receptorGLP-1 receptor

Research summary

Amgen bispecific molecule (GIPR antagonist + GLP-1R agonist) in Phase 2/3 obesity development. Monthly-class PK in trials. Not FDA-approved.

Research evidence

  • Regulatory review (FDA label)None in reviewed sources
  • Controlled human trials3 reviewed sources
  • Early or uncontrolled human studiesNone in reviewed sources
  • Lab & animal studiesNone in reviewed sources
How it works

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

Peptide Library's Maridebart cafraglutide profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.

Maridebart cafraglutide dosage evidence

Maridebart cafraglutide (MariTide) has no approved dosage. Human dosing comes from Amgen's phase 2 obesity trial, which gave 140, 280 or 420 mg under the skin every 4 weeks, or 420 mg every 8 weeks, for 52 weeks; mean weight change ranged from -12.3% to -16.2% against -2.5% with placebo in people without diabetes. Phase 3 trials are under way, and their registry entries list low, medium and high doses without amounts.

Clinical Trial Evidence
Dosage evidence summary for Maridebart cafraglutide
Human dosing establishedYes
Studied dose range140–420 mg every 4 or 8 weeks in the phase 2 trial
RouteSubcutaneous
FrequencyEvery 4 weeks or every 8 weeks
Duration studied52 weeks in the phase 2 trial; 72 weeks planned in the MARITIME-1 phase 3 trial
TitrationPhase 2 compared starting at full dose with 4-week and 12-week dose escalation to 420 mg; gastrointestinal effects were less frequent with escalation and a lower starting dose.
Evidence levelClinical Trial Evidence
Last reviewed2026-11-07

Research-reported dosing

Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.

Research-reported dosing for Maridebart cafraglutide, one row per studied regimen
Study / contextPopulationDoseRouteFrequencyDurationOutcome studiedSource
Phase 2 dose-ranging, obesity cohort (NCT05669599)Clinical trial · Randomized, double-blind, placebo-controlled phase 2 trialAdults with obesity without type 2 diabetes (n=465)140, 280 or 420 mg every 4 weeks, or 420 mg every 8 weeks, with or without dose escalationSubcutaneousEvery 4 or 8 weeks52 weeksMean body-weight change at week 52 from -12.3% to -16.2% across groups, against -2.5% with placeboOnce-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial. N Engl J Med. 2025.
Phase 2 dose-ranging, obesity with type 2 diabetes cohort (NCT05669599)Clinical trial · Randomized, double-blind, placebo-controlled phase 2 trialAdults with obesity and type 2 diabetes (n=127)140, 280 or 420 mg, without dose escalationSubcutaneousEvery 4 weeks52 weeksMean body-weight change from -8.4% to -12.3% against -1.7% with placebo; HbA1c fell 1.2 to 1.6 percentage pointsOnce-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial. N Engl J Med. 2025.
Phase 1 single and multiple ascending doses (NCT04478708)Clinical trial · Randomized, double-blind, placebo-controlled phase 1 studyParticipants with obesity (n not stated in the indexed abstract)Single and multiple ascending doses; amounts not stated in the indexed abstractSubcutaneousNot stated in the indexed abstractNot stated in the indexed abstractDose-dependent weight loss, maintained up to 150 days after the last dose in the multiple-dose cohortsA GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings. Nat Metab. 2024.
MARITIME-1 — phase 3, obesity without diabetes (NCT06858839)Clinical trial · Phase 3 randomized, placebo-controlled trial, active not recruitingAdults with obesity or overweight without type 2 diabetes (n=3,853)Low, medium or high dose (amounts not given in the registry)SubcutaneousPer trial protocol72 weeksOngoing; no results postedNCT06858839 — Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

Where sources disagree

  • Maridebart cafraglutide is an antibody joined to two GLP-1 peptides, so its doses are hundreds of milligrams given monthly or less often. These amounts are not comparable to weekly GLP-1 drugs dosed in single milligrams.
  • The phase 3 doses are not public in the registry, which lists only low, medium and high arms. The phase 2 doses may not be the ones finally carried forward.
  • It is not FDA-approved.
Maridebart cafraglutide dosage in published studies and labels →

Handling & administration

Injection Sites
Per protocol
Timing Notes
Phase 2 obesity; Phase 3 CV/HFpEF programs initiated

Sequence & molecular data

Sequence and molecular data for Maridebart cafraglutide
Molecular formula— (antibody–peptide conjugate; very high MW)
Molecular weight≈145–154 kDa (conjugate; assay-dependent)
CAS number2760218-55-9
Half-lifeLong (monthly or less frequent dosing in trials)
AppearanceSterile solution for sc injection (investigational)
FormulationSolution

Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.

Science

Mechanism of Action

Maridebart cafraglutide is an antibody-peptide conjugate with an unusual design: it antagonises the GIP receptor while activating the GLP-1 receptor. A monoclonal antibody against GIPR is conjugated to GLP-1 analog peptides, so one molecule blocks one incretin receptor and stimulates the other. This is the opposite of the tirzepatide approach, which agonises both, and the fact that GIPR agonism and antagonism have each produced weight reduction in trials remains an unresolved question in incretin pharmacology. The antibody scaffold gives a long half-life supporting infrequent dosing. It is investigational.

Origin

Engineered monoclonal antibody–peptide conjugate.

Targets

GIP receptorGLP-1 receptor

Research statistics

11 PubMed publications · 18.2% human clinical research · 32 registered trials

Counts of published research through 2026-11-15, not evidence that it works. Publications by year, study types and trials · How publications are counted

Regulatory & research status

Maridebart cafraglutide has been studied under an Investigational New Drug application. It is not approved for marketing.

Regulatory and research status for Maridebart cafraglutide
FDA statusInvestigational New Drug (IND)
AvailabilityResearch-Only
WADA (sport)Banned in Sport
Library classificationClinical Trial

How FDA approval, compounding and research-only status differ

Benefits

Investigational obesity candidateInfrequent-dosing research

Maridebart cafraglutide side effects

The effects below are those reported in Maridebart cafraglutide clinical trials; long-term safety data may still be limited.

Side Effects

  • GI effects
  • Antibody-related reactions possible

Storage & stability

This compound is not supplied as a powder to be mixed, so the freeze-dried powder and reconstitution handling described for research peptides does not apply. Storage conditions are product-specific: follow the label or packaging of the product itself.

Maridebart cafraglutide: frequently asked questions

What is Maridebart cafraglutide?

Amgen bispecific molecule (GIPR antagonist + GLP-1R agonist) in Phase 2/3 obesity development. Monthly-class PK in trials. Not FDA-approved.

How does Maridebart cafraglutide work?

Maridebart cafraglutide is an antibody-peptide conjugate with an unusual design: it antagonises the GIP receptor while activating the GLP-1 receptor. A monoclonal antibody against GIPR is conjugated to GLP-1 analog peptides, so one molecule blocks one incretin receptor and stimulates the other.

Is Maridebart cafraglutide FDA approved?

No. Maridebart cafraglutide is investigational: it is in clinical development and has not been approved by the FDA for any indication. Investigational status means trials are ongoing or complete but regulatory review has not resulted in approval, and efficacy and safety are still being established.

What is the half-life of Maridebart cafraglutide?

Reported half-life for Maridebart cafraglutide is Long (monthly or less frequent dosing in trials). Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.

Is Maridebart cafraglutide banned in sport?

Maridebart cafraglutide is recorded here as prohibited in sport. Athletes subject to anti-doping rules should check the current WADA Prohibited List directly, since it is revised annually and classifications change.

What peptides are similar to Maridebart cafraglutide?

Compounds most often compared with Maridebart cafraglutide include Retatrutide, Survodutide, Pemvidutide and Cotadutide. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

References

Related research, comparisons & guides

Related peptides

Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Nov 7, 2026 · Version 2

This Maridebart cafraglutide profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error

Track Maridebart cafraglutide research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →